Home > Keywords > Thématique > Finances

Finances

Articles

  • Vect-Horus poursuit le renforcement son équipe de direction en nommant Carole Imbert au poste de Directrice Financière
    25 March, by Emmanuelle BETTENDORF

    We are thrilled to welcome Carole Imbert to our executive management team as our new Chief Financial Officer.
    “Her extensive background in financial strategy and investor relations will be complementary to our existing skilled team, and an invaluable asset to drive our growth and secure a strong financial position to underpin development of our vectors that facilitate targeting and delivery of therapeutics,” says @Alexandre Tokay, co-founder and CEO of Vect-Horus.
    “Carole’s leadership (…)

  • Vect-Horus completes its €12 Million fund-raising operation
    20 January 2021, by Elodie DORMES

    Vect-Horus completes its Series D with private investors for a total amount of € 12 million to strengthen company’s effort in identification of new vectors, development of theragnostic agents and delivering of biologics and nucleic acids.

  • Vect-Horus raises 3.5M€ to accelerate its development programs
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS, a biotechnology company that designs and develops vectors facilitating targeting of therapeutic molecules and imaging agents, announces completion of a new fund-raising round for 3.5 million euros, following a previous round of 2.5 million euros in 2017. In this new round participated historic shareholders and also new entrants including CAAP Création, a subsidiary of Crédit Agricole Alpes Provence, Financière Tuileries Co-Invest and SCR Provençale et Corse, subsidiary of Banque (…)

  • Vect-Horus reçoit un financement non dilutif de 1M(e) dans le cadre du dispositif de relance Européen REACT-EU
    2 February 2022, by Elodie DORMES

    Vect-Horus annonce l’accord de la Région SUD Provence-Alpes-Côte d’Azur pour une subvention de plus d’un million d’euros.

  • Fifth round of funding
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS has completed a fifth round of venture capital funding from private shareholders.

  • Fourth round of financing
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS has completed a fourth round of venture capital funding from private shareholders.

  • Vect-Horus raises €6.7 Million to further develop its VECTrans® Platform
    9 September 2020, by Elodie DORMES

    Vect-Horus raises €6.7 million to further develop its VECTrans® platform and the clinical trial of its first theragnostic agent.

  • Vect-Horus announces a new equity issue of 1.5 M€ to finance the preclinical development of its first vectorized product
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS announced today having raised € 1.5 million, from its historical shareholders, mostly professionals in the finance industry. In total, VECT-HORUS raised in 9 years more than € 11 million, of which € 5 million in grants and research tax credit, a record in France for equity financing of a biotechnology company.
    The public-private research collaboration developed with the CNRS, Aix -Marseille University (AMU), the CEA and INSERM has allowed VECT-HORUS to develop a portfolio of (…)

  • Vect-Horus raises 2.5 M€ to finance its development projects in the “targeted therapy” field
    28 January 2019, by Jonathan NOWAK

    Marseille, 22 Mars 2017 - The French biotechnology start up VECT-HORUS, a European leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, announces completion of a new fund raising round for 2.5 million euros, from private shareholders including Société de Capital Risque (SCR) Provençale et Corse, a wholly owned subsidiary of Banque Populaire Méditerranée (BPMed). Since its creation, VECT-HORUS raised over 17 M€, including 6 M€ in grants and (…)

  • Vect-Horus reçoit une subvention pour le développement de sa plateforme VECTrans® dans le domaine de l’ophtalmologie
    6 October 2022, by Elodie DORMES

    MARSEILLE, France—Vect-Horus, une société de biotechnologie qui conçoit et développe des vecteurs permettant l’adressage ciblé de molécules thérapeutiques et d’agents d’imagerie vers différents organes dont le cerveau, annonce l’accord de Bpifrance et de la Région SUD Provence-Alpes-Côte d’Azur pour l’octroi d’une subvention de 200.000 € visant à soutenir son projet VISIO (Vectorisation Innovante de siRNAs pour l’Ophtalmologie).
    Cette subvention permettra d’étendre les efforts de la (…)